Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DR26FQST2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,951
Award facts
- Contract value 100% obligated
- $18,950.64 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $18,950.64 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 150 mg/ml Xolair syringes. This delivery order was issued without a set-aside designation on November 4, 2025, with an ultimate completion date of November 26, 2025. Xolair is a biologic immunosuppressant commonly used to treat moderate-to-severe allergic asthma and chronic spontaneous urticaria, reflecting the Defense Logistics Agency's need to stock specialized pharmaceutical products for military healthcare facilities.
This delivery order was issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, valued at $499.999 billion through December 31, 2036. As a regional prime vendor contractor within this $30.3 billion acquisition strategy, DMS Pharmaceutical Group is positioned to supply a comprehensive range of branded and generic pharmaceuticals, biologics, vaccines, and medical consumables to support Department of Defense healthcare operations globally. The company's established performance across numerous recent delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FQST2?
SPE2DR26FQST2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 4, 2025.
How much is contract SPE2DR26FQST2 worth?
The government has obligated $18,951 on SPE2DR26FQST2.
Is contract SPE2DR26FQST2 an order under another contract?
Yes. SPE2DR26FQST2 is a delivery order under SPE2DR25D9214, an indefinite delivery contract.
Was contract SPE2DR26FQST2 competed?
The extent of competition for SPE2DR26FQST2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award